Effect of Diabetes Mellitus and Metformin Usage on Treatment Outcomes and Side Effects on Prostate Cancer Treated with Radical Radiotherapy

DAĞDELEN M., BARLAS C., Yildirim C., KARAÇAM S., DİNÇBAŞ H. F.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, vol.20, no.3, pp.162-167, 2021 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.4274/uob.galenos.2020.1830
  • Journal Name: UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.162-167
  • Keywords: Prostate cancer, diabetes mellitus, metformin, radiotherapy, side effects, THERAPY, HYPERGLYCEMIA, ASSOCIATION, MANAGEMENT, RECURRENCE, MORTALITY
  • Istanbul University Affiliated: No

Abstract

Objective: Diabetes mellitus (DM) is a common comorbidity in patients with prostate cancer. Radiotherapy was reported to induce acute and late side effects in patients with DM due to vascular damage. Moreover, some studies have shown that metformin, an oral antidiabetic drug, can reduce biochemical and disease recurrence in patients with prostate cancer. This study aimed to evaluate retrospectively the effect of metformin on biochemical disease control and to observe the acute and late side effects of prostate cancer treated with radiotherapy.